A mathematical model shows that mutations that recur even modestly among cancer patients are cancer driving nucleotides that can be exhaustively identified to serve as targets of cancer therapy.
Katherine A Senn, Karli A Lipinski ... Aaron A Hoskins
The Saccharomyces cerevisiae spliceosome component Fyv6 contributes to precursor messenger RNA splicing by promoting use of branch site distal 3' splice sites and interacting with key factors involved in exon ligation.
Analyses of discovered cancer-driving nucleotides (CDNs) reveal their evolutionary, biochemical, and therapeutic characteristics that are often shared among multiple cancer types.
Somatic mutations frequently disrupt cleavage and polyadenylation signals in tumour suppressor genes in human cancers, likely contributing to tumour progression.
During zebrafish embryogenesis, dact1 and dact2 are necessary for axis lengthening and craniofacial morphogenesis, and the protease capn8 is misexpressed in dact1/2 mutants.
SIRT4 regulates cellular communication network factor 2 expression through U2 small nuclear RNA auxiliary factor 2-mediated pre-mRNA splicing, presenting a potential therapeutic target for kidney fibrosis.
An enhancer-dependent transcriptional machinery finely tunes the expression of Ctnnb1 in intestinal crypts, thereby balancing homeostasis and tumorigenesis of intestinal epithelia.
